COP vs IMRX · P/E 19, rev $58.94B vs $124.2M cap
ConocoPhillips (COP) versus Immuneering Corp (IMRX) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
COP currently screens at market cap $135.49B and trailing P/E 18.8. IMRX currently screens at market cap $124.2M.
Not investment advice. Open the COP and IMRX stock pages for the full models.
Not investment advice.